{{Rsnum
|rsid=1413845
|Gene=SLC35F1
|Chromosome=6
|position=118206855
|Orientation=minus
|GMAF=0.4444
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC35F1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 46.9 | 45.1 | 8.0
| HCB | 14.6 | 46.7 | 38.7
| JPT | 1.8 | 33.0 | 65.2
| YRI | 68.0 | 30.6 | 1.4
| ASW | 49.1 | 36.8 | 14.0
| CHB | 14.6 | 46.7 | 38.7
| CHD | 14.7 | 47.7 | 37.6
| GIH | 38.6 | 44.6 | 16.8
| LWK | 66.4 | 31.8 | 1.8
| MEX | 17.5 | 47.4 | 35.1
| MKK | 57.1 | 34.6 | 8.3
| TSI | 40.6 | 40.6 | 18.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1413845
|Name_s=
|Gene_s=SLC35F1
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.39, combined P value= 2.48E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470219
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1413845
|overall_frequency_n=78
|overall_frequency_d=126
|overall_frequency=0.619048
|n_genomes=45
|n_genomes_annotated=0
|n_haplomes=66
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}